Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 8, Pages 854
Publisher
MDPI AG
Online
2019-08-08
DOI
10.3390/cells8080854
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Age-related inflammation triggers skeletal stem/progenitor cell dysfunction
- (2019) Anne Marie Josephson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- L1 drives IFN in senescent cells and promotes age-associated inflammation
- (2019) Marco De Cecco et al. NATURE
- Cutting Edge: G Protein Subunit β 1 Negatively Regulates NLRP3 Inflammasome Activation
- (2019) Tomohiko Murakami et al. JOURNAL OF IMMUNOLOGY
- JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates
- (2019) Salvador C. Herrera et al. DEVELOPMENT
- Thromboembolic events in polycythemia vera
- (2019) Martin Griesshammer et al. ANNALS OF HEMATOLOGY
- Effect of Chronic Hematologic Malignancies on In-hospital Outcomes of Patients with ST-Segment Elevation Myocardial Infarction
- (2019) Gaurav Patel et al. AMERICAN JOURNAL OF CARDIOLOGY
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
- (2018) Barbara Mora et al. HAEMATOLOGICA
- Age-related cognitive impairment is associated with long-term neuroinflammation and oxidative stress in a mouse model of episodic systemic inflammation
- (2018) Joana Costa d’Avila et al. Journal of Neuroinflammation
- Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
- (2018) Marlies Meisel et al. NATURE
- Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells
- (2018) Richard K. Lubberich et al. PLoS One
- Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms
- (2018) Ofir Wolach et al. Science Translational Medicine
- Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
- (2018) Alessandro Prestipino et al. Science Translational Medicine
- Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
- (2018) Valerio De Stefano et al. Blood Cancer Journal
- Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project
- (2018) Barbara Mora et al. HAEMATOLOGICA
- JAK/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation
- (2018) Camilla A. Richmond et al. Stem Cell Reports
- Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
- (2018) Tamas Fulop et al. Frontiers in Immunology
- Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
- (2018) Irene Maeve Rea et al. Frontiers in Immunology
- Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations
- (2018) Stanley Chun-Wei Lee et al. CANCER CELL
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis
- (2018) Anna Berekmeri et al. Expert Review of Clinical Immunology
- JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
- (2018) Bärbel Edelmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
- (2018) Sebastien Jacquelin et al. BLOOD
- Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis
- (2018) Zhigang Cai et al. Cell Stem Cell
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
- (2018) S. A. Kerrigan et al. Current Rheumatology Reports
- Tet2 restrains inflammatory gene expression in macrophages
- (2017) Alyssa H. Cull et al. EXPERIMENTAL HEMATOLOGY
- The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression
- (2017) Wen Pan et al. IMMUNITY
- Impact of tofacitinib treatment on human B-cells in vitro and in vivo
- (2017) Marta Rizzi et al. JOURNAL OF AUTOIMMUNITY
- Genomics of Myeloproliferative Neoplasms
- (2017) Katerina Zoi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Gain of function in Jak2V617F-positive T-cells
- (2017) G Nishanth et al. LEUKEMIA
- JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
- (2017) N Gupta et al. LEUKEMIA
- Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2
- (2017) S Bartels et al. LEUKEMIA
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dnmt3arestrains mast cell inflammatory responses
- (2017) Cristina Leoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inflammation and metabolism in tissue repair and regeneration
- (2017) Sabine A. Eming et al. SCIENCE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development
- (2017) Morten Andersen et al. PLoS One
- Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- (2016) A Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- The E3 Ubiquitin Ligase c-Cbl Inhibits Microglia-Mediated CNS Inflammation by Regulating PI3K/Akt/NF-κB Pathway
- (2016) Lin Dong et al. CNS Neuroscience & Therapeutics
- JAK/STAT signalling mediates cell survival in response to tissue stress
- (2016) Marco La Fortezza et al. DEVELOPMENT
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
- (2016) Holly L. Geyer et al. HAEMATOLOGICA
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration
- (2016) Hongwei Qin et al. JOURNAL OF NEUROSCIENCE
- A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
- (2016) S Verstovsek et al. LEUKEMIA
- Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
- (2016) S Koschmieder et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms
- (2016) Luigi Gugliotta et al. LEUKEMIA RESEARCH
- Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
- (2016) L Kahl et al. LUPUS
- Reparative inflammation takes charge of tissue regeneration
- (2016) Michael Karin et al. NATURE
- Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
- (2016) Ming Xu et al. PHARMACOLOGICAL RESEARCH
- Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
- (2016) Andrew L. Young et al. Nature Communications
- Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
- (2016) Holly L. Geyer et al. HAEMATOLOGICA
- Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
- (2016) Alberto Alvarez-Larrán et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans
- (2016) Shai S. Shen-Orr et al. Cell Systems
- Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) A. M. Vannucchi et al. ANNALS OF ONCOLOGY
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
- (2015) Clodagh Keohane et al. BRITISH JOURNAL OF HAEMATOLOGY
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
- (2015) F Perner et al. LEUKEMIA
- The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
- (2015) Jonas S. Jutzi et al. MEDIATORS OF INFLAMMATION
- A gp130–Src–YAP module links inflammation to epithelial regeneration
- (2015) Koji Taniguchi et al. NATURE
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
- (2015) Qian Zhang et al. NATURE
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice
- (2015) Raasay S. Jones et al. NEUROBIOLOGY OF AGING
- Effect of Mutation Order on Myeloproliferative Neoplasms
- (2015) Christina A. Ortmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age
- (2015) Ming Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
- (2015) J. Nangalia et al. HAEMATOLOGICA
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro
- (2014) Sheau-Pey Wang et al. ANNALS OF THE RHEUMATIC DISEASES
- Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
- (2014) L. Lamrani et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
- (2014) P. Lundberg et al. BLOOD
- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Age-Associated Loss of Lamin-B Leads to Systemic Inflammation and Gut Hyperplasia
- (2014) Haiyang Chen et al. CELL
- Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
- (2014) S. C. Meyer et al. CLINICAL CANCER RESEARCH
- Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressingJAK2-V617F
- (2014) Pontus Lundberg et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Jak/Stat Signaling Stimulates Zebrafish Optic Nerve Regeneration and Overcomes the Inhibitory Actions of Socs3 and Sfpq
- (2014) F. Elsaeidi et al. JOURNAL OF NEUROSCIENCE
- Inhibition of JAK-STAT signaling stimulates adult satellite cell function
- (2014) Feodor D Price et al. NATURE MEDICINE
- The impact of JAK-STAT signaling on muscle regeneration
- (2014) Jason D Doles et al. NATURE MEDICINE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
- (2014) Jaebok Choi et al. PLoS One
- JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
- (2014) S. Leah Etheridge et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia
- (2013) C. M. Hobbs et al. BLOOD
- Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
- (2013) J. Wehrle et al. HAEMATOLOGICA
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
- (2013) Jonas S. Jutzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
- (2013) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- No Evidence for JAK2V617F Mutation in Monoclonal B Cells in 2 Patients with Polycythaemia Vera and Concurrent Monoclonal B Cell Disorder
- (2012) C. Stijnis et al. ACTA HAEMATOLOGICA
- JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway
- (2012) M. De Grandis et al. BLOOD
- Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
- (2012) H. C. Hasselbalch BLOOD
- Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation
- (2012) V. Rosti et al. BLOOD
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- Divergent requirement for Gαs and cAMP in the differentiation and inflammatory profile of distinct mouse Th subsets
- (2012) Xiangli Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
- (2012) Lambert Busque et al. NATURE GENETICS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute Inflammation Initiates the Regenerative Response in the Adult Zebrafish Brain
- (2012) N. Kyritsis et al. SCIENCE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Endothelial progenitor cells are clonal and exhibit the JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms
- (2011) L. Teofili et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells
- (2011) Brad Dykstra et al. JOURNAL OF EXPERIMENTAL MEDICINE
- p53 Lesions in Leukemic Transformation
- (2011) Ashot Harutyunyan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms
- (2010) F. X. Schaub et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
- (2010) O. Abdel-Wahab et al. CANCER RESEARCH
- JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
- (2010) A Pardanani et al. LEUKEMIA
- LNK mutation studies in blast-phase myeloproliferative neoplasms and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
- (2010) A Pardanani et al. LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner
- (2010) C. Rathinam et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion
- (2010) I. Beerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome
- (2009) S. Sozer et al. BLOOD
- Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm
- (2009) P. A. Beer et al. BLOOD
- Cytokine/Jak/Stat Signaling Mediates Regeneration and Homeostasis in the Drosophila Midgut
- (2009) Huaqi Jiang et al. CELL
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular inflammation: Underpinnings of aging and age-related diseases
- (2008) Hae Young Chung et al. AGEING RESEARCH REVIEWS
- Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F
- (2008) F. X. Schaub et al. BLOOD
- Cytokine Signaling Modules in Inflammatory Responses
- (2008) John J. O'Shea et al. IMMUNITY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started